These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 35511579)

  • 1. The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.
    Glhoom S; Fergany A; El-Araby D; Abdelkhalek AA; Gomaa A; Zayed EO; Abd-ElGwad M
    Eur J Med Res; 2024 Jan; 29(1):27. PubMed ID: 38183123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis.
    Morgan HJ; Clothier HJ; Sepulveda Kattan G; Boyd JH; Buttery JP
    Vaccine; 2024 Apr; 42(9):2212-2219. PubMed ID: 38350771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Evusheld safety and efficacy in multiple sclerosis patients.
    Liu EN; Real M; Yang JH; Fair A; Whitmire N; Perez A; Wilder C; Rosengren S; Kinkel RP; Graves JS
    Mult Scler Relat Disord; 2024 Jun; 88():105733. PubMed ID: 38901372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system immune-related disorders after SARS-CoV-2 vaccination: a multicenter study.
    Vogrig A; Tartaglia S; Dentoni M; Fabris M; Bax F; Belluzzo M; Verriello L; Bagatto D; Gastaldi M; Tocco P; Zoccarato M; Zuliani L; Pilotto A; Padovani A; Villagrán-García M; Davy V; Gigli GL; Honnorat J; Valente M
    Front Immunol; 2024; 15():1344184. PubMed ID: 38375477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons of the month 1: Longitudinal extensive transverse myelitis following AstraZeneca COVID-19 vaccination.
    Notghi AA; Atley J; Silva M
    Clin Med (Lond); 2021 Sep; 21(5):e535-e538. PubMed ID: 34507942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients.
    Marti-Pastor M; Bou-Monterde R; Ciancotti-Oliver L; Alcover-Pons M; Amorós Cantero A; Sánchez-Lopezosa R; Montañana-Rosell N
    Med Clin (Barc); 2024 Jun; ():. PubMed ID: 38937218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subacute transverse myelitis of possible vasculitic origin after SARS-CoV2 and Varicella-Zoster virus infections: a case report.
    Favruzzo F; Palmieri A; Giopato F; Cardellini D; Vidali A; Bonifati DM
    J Neurol; 2024 Jan; 271(1):75-78. PubMed ID: 38070029
    [No Abstract]   [Full Text] [Related]  

  • 8. Comprehensive procedure for injecting Evusheld® for hematological diseases in a single institute.
    Imataki O; Yoshida S; Ishida T; Uemura M; Fujita H; Kadowaki N
    Ann Hematol; 2024 May; ():. PubMed ID: 38734996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 update: An EUA for pemivibart (Pemgarda) for pre-exposure prophylaxis.
    Med Lett Drugs Ther; 2024 May; 66(1702):79-80. PubMed ID: 38696314
    [No Abstract]   [Full Text] [Related]  

  • 10. Discursive trends in New York Times coverage of Evusheld access: A case study in the social production of ignorance.
    Goggins S
    Soc Sci Med; 2024 May; 349():116855. PubMed ID: 38642521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: The Rehabilitation of a Patient with Acute Transverse Myelitis after COVID-19 Vaccination.
    Niebrzydowski P; Kusiak-Kaczmarek M; Tomaszewski J; Gmiński M; Szalewska D
    Clin Pract; 2024 Jun; 14(3):1076-1084. PubMed ID: 38921263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2-related myelitis: two cases from a major neurological clinic in Central Italy.
    Giovannini B; Bianchi F; Montano V; Siciliano G; Pasquali L
    Neurol Sci; 2024 May; 45(5):1845-1848. PubMed ID: 38315251
    [No Abstract]   [Full Text] [Related]  

  • 13. [Acute transverse myelitis following SARS-CoV-2 infection].
    Jauregui-Larrañaga C; Ostolaza-Ibáñez A; Martín-Bujanda M
    Neurologia; 2021 Sep; 36(7):572-574. PubMed ID: 38620787
    [No Abstract]   [Full Text] [Related]  

  • 14. Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study.
    Nassar MK; Sabry A; Elgamal M; Zeid Z; Abdellateif Abdelghany D; Tharwat S
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138212
    [No Abstract]   [Full Text] [Related]  

  • 15. COVID-19 and Pregnancy.
    Chowdhury S; Bappy MH; Desai S; Chowdhury S; Patel V; Chowdhury MS; Fonseca A; Sekzer C; Zahid S; Patousis A; Gerothanasi A; Masenga MJ
    Discoveries (Craiova); 2022; 10(2):e147. PubMed ID: 36438440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 vaccine associated transverse myelitis-Evusheld as an option when vaccination is not recommended due to severe adverse events.
    Fitzsimmons WE
    Hum Vaccin Immunother; 2022 Nov; 18(5):2068338. PubMed ID: 35511579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database.
    Nguyen S; Bastien E; Chretien B; Sassier M; Defer G; Nehme A; Lelong-Boulouard V; Alexandre J; Fedrizzi S; Morice PM
    Ann Neurol; 2022 Dec; 92(6):1080-1089. PubMed ID: 36054163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinally extensive transverse myelitis after Covid-19 vaccination: case report and review of literature.
    Maroufi SF; Naderi Behdani F; Rezania F; Tanhapour Khotbehsara S; Mirzaasgari Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):2040239. PubMed ID: 35240927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consider Transverse Myelitis as a Complication of a SARS-CoV-2 Vaccination.
    Finsterer J; Matovu D
    J Korean Med Sci; 2022 May; 37(18):e150. PubMed ID: 35535377
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.